IFNB1 and myeloid sarcoma: There are several approved drugs for MS patients, including natalizumab, ocrelizumab, alemtuzumab, interferon beta (IFNβ), glatiramer acetate (GA), mitoxantrone, dimethyl fumarate, fingolimod, teriflunomide, and cladribine.